"How can we best implement a PrEP program in a community-based health center?"

Pre-Exposure Prophylaxis (PrEP) is a strategy that involves the use of anti-HIV medications (also called antiretrovirals, or ARVs) by HIV-negative individuals to reduce the risk of HIV infection via sexual exposure. In 2012, the US Food and Drug Administration (FDA) approved the drug, Truvada, for daily oral use as PrEP.

This project is a collaboration between HART and Callen-Lorde Community Health Center (CLCHC), the largest LGBT community health provider in New York City. The study is the first community-based demonstration project to be fully integrated into a community healthcare setting, and it is designed to evaluate a program in which PrEP is introduced, provided, and supported as part of a comprehensive prevention package. The project is also designed to identify and examine social and behavioral factors associated with disparities in access to prevention and care services among gay, bisexual, and other men who have sex with men in NYC that might direct or impact PrEP implementation programs and policies.

Click here to view the SPARK website.

Funded by:
The National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Grant #: R01AA022067
Dates: 09/2012 - 07/2017
PI: Sarit A. Golub, PhD, MPH